Financial Gravity Companies’s PDL BioPharma, Inc. PDLI Stock Holding History

Financial Gravity Companies’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$3	Buy	+33	New	+$3	﹤0.01%	979
2024 Q4	$0	Buy	+32	New	–	﹤0.01%	1029
2018 Q4	$0	Buy	+153	New	+$420	﹤0.01%	1601
2018 Q1	$1K	Sell	229 -12,767	-98%	-$34.8K	﹤0.01%	1364
2017 Q4	$36K	Buy	+12,996	New	+$39.9K	0.04%	389

Other funds holding PDLI

Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Financial Gravity Companies's PDLI Position: Q2 2025 in Review

Financial Gravity Companies opened a new position in PDL BioPharma, Inc. (PDLI) in Q2 2025: 33 shares worth $3. The stake represents ﹤0.01% of the portfolio and ranks #979 among its holdings. This is a return to the name: Financial Gravity Companies previously reported a position in PDLI as recently as Q4 2024.

Financial Gravity Companies first reported a position in PDLI in Q4 2017 and has held it in 5 quarters since. The position peaked at $36K in Q4 2017. 7 funds tracked by Wall St. Rank hold PDLI as of Q2 2025.

Financial Gravity Companies held 33 shares of PDL BioPharma, Inc. worth $3 as of Q2 2025.
PDL BioPharma, Inc. was a new Financial Gravity Companies position in Q2 2025.
PDL BioPharma, Inc. made up ﹤0.01% of Financial Gravity Companies's portfolio in Q2 2025, its #979 holding.
Financial Gravity Companies first reported a position in PDL BioPharma, Inc. in Q4 2017 and has held it in 5 quarters since.
Financial Gravity Companies's PDL BioPharma, Inc. position peaked at $36K in Q4 2017.
7 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2025.

Based on Financial Gravity Companies's 13F filing for Q2 2025, filed 8 Aug 2025.